Bellerophon Therapeutics (NASDAQ:BLPH) Receives New Coverage from Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

Shares of NASDAQ:BLPH opened at $0.05 on Monday. The business’s 50 day moving average price is $0.05 and its 200-day moving average price is $0.06. The firm has a market capitalization of $665,312.00, a PE ratio of -0.06 and a beta of 0.67. Bellerophon Therapeutics has a 1 year low of $0.03 and a 1 year high of $11.15.

Institutional Trading of Bellerophon Therapeutics

A number of institutional investors have recently made changes to their positions in the company. State Street Corp boosted its stake in shares of Bellerophon Therapeutics by 41.3% in the first quarter. State Street Corp now owns 30,127 shares of the biotechnology company’s stock worth $238,000 after acquiring an additional 8,800 shares during the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of Bellerophon Therapeutics in the first quarter worth approximately $107,000. Renaissance Technologies LLC boosted its stake in shares of Bellerophon Therapeutics by 13.0% in the second quarter. Renaissance Technologies LLC now owns 209,399 shares of the biotechnology company’s stock worth $258,000 after acquiring an additional 24,100 shares during the last quarter. HRT Financial LP acquired a new stake in shares of Bellerophon Therapeutics in the fourth quarter worth approximately $25,000. Finally, Geode Capital Management LLC boosted its stake in shares of Bellerophon Therapeutics by 49.0% in the first quarter. Geode Capital Management LLC now owns 95,656 shares of the biotechnology company’s stock worth $755,000 after acquiring an additional 31,460 shares during the last quarter. 10.61% of the stock is owned by institutional investors and hedge funds.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.